S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30

ICON Public Stock Forecast, Price & News

+4.10 (+1.63%)
(As of 01/24/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
567,057 shs
Average Volume
656,357 shs
Market Capitalization
$13.53 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ICLR News and Ratings via Email

Sign-up to receive the latest news and ratings for ICON Public and its competitors with MarketBeat's FREE daily newsletter.

ICON Public logo

About ICON Public

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the strategic development, management and analysis of programs that support clinical development. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.


See More Headlines

Industry, Sector and Symbol

Commercial physical research
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$2.80 billion
Cash Flow
$8.31 per share
Book Value
$34.51 per share


Net Income
$332.33 million
Pretax Margin




Free Float
Market Cap
$13.53 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.34 out of 5 stars

Medical Sector

249th out of 1,415 stocks

Commercial Physical Research Industry

7th out of 27 stocks

Analyst Opinion: 2.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 3.1 5 -4 -3 -2 -1 -

ICON Public (NASDAQ:ICLR) Frequently Asked Questions

Is ICON Public a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ICON Public in the last twelve months. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ICON Public stock.
View analyst ratings for ICON Public
or view top-rated stocks.

How has ICON Public's stock price been impacted by Coronavirus?

ICON Public's stock was trading at $152.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ICLR shares have increased by 67.9% and is now trading at $256.05.
View which stocks have been most impacted by COVID-19

When is ICON Public's next earnings date?

ICON Public is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for ICON Public

How were ICON Public's earnings last quarter?

ICON Public Limited (NASDAQ:ICLR) announced its earnings results on Wednesday, November, 3rd. The medical research company reported $2.55 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $2.39 by $0.16. The medical research company had revenue of $1.87 billion for the quarter, compared to the consensus estimate of $1.84 billion. ICON Public had a net margin of 4.09% and a trailing twelve-month return on equity of 15.50%. The firm's quarterly revenue was up 166.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.72 earnings per share.
View ICON Public's earnings history

What guidance has ICON Public issued on next quarter's earnings?

ICON Public issued an update on its FY22 earnings guidance on Wednesday, January, 12th. The company provided EPS guidance of $11.55-11.95 for the period, compared to the Thomson Reuters consensus EPS estimate of $11.36. The company issued revenue guidance of $7.77-8.05 billion, compared to the consensus revenue estimate of $7.95 billion.

What price target have analysts set for ICLR?

12 analysts have issued 12-month target prices for ICON Public's shares. Their forecasts range from $232.00 to $320.00. On average, they anticipate ICON Public's stock price to reach $282.36 in the next twelve months. This suggests a possible upside of 10.3% from the stock's current price.
View analysts' price targets for ICON Public
or view top-rated stocks among Wall Street analysts.

Who are ICON Public's key executives?

ICON Public's management team includes the following people:
  • Stephen A. Cutler, Chief Executive Officer & Executive Director
  • Brendan Brennan, Chief Financial Officer
  • Tom O'Leary, Chief Information Officer
  • Gregory P. Licholai, Chief Medical & Innovation Officer
  • Diarmaid Cunningham, Secretary, Chief Administrative Officer & EVP

What is Steve Cutler's approval rating as ICON Public's CEO?

147 employees have rated ICON Public CEO Steve Cutler on Glassdoor.com. Steve Cutler has an approval rating of 63% among ICON Public's employees. This puts Steve Cutler in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ICON Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ICON Public investors own include Pfizer (PFE), Gilead Sciences (GILD), Visa (V), NVIDIA (NVDA), CVS Health (CVS), UnitedHealth Group (UNH), Alibaba Group (BABA), Walt Disney (DIS), Home Depot (HD) and Johnson & Johnson (JNJ).

What is ICON Public's stock symbol?

ICON Public trades on the NASDAQ under the ticker symbol "ICLR."

Who are ICON Public's major shareholders?

ICON Public's stock is owned by a variety of retail and institutional investors. Top institutional investors include Russell Investments Group Ltd. (0.23%), CHURCHILL MANAGEMENT Corp (0.04%), Icon Wealth Partners LLC (0.01%), Private Trust Co. NA (0.00%), Tributary Capital Management LLC (0.00%) and Parallel Advisors LLC (0.00%).

Which institutional investors are selling ICON Public stock?

ICLR stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Parallel Advisors LLC, Private Trust Co. NA, and CHURCHILL MANAGEMENT Corp.

Which institutional investors are buying ICON Public stock?

ICLR stock was acquired by a variety of institutional investors in the last quarter, including Sara Bay Financial, Lindbrook Capital LLC, Tributary Capital Management LLC, Whittier Trust Co. of Nevada Inc., Icon Wealth Partners LLC, and IFP Advisors Inc.

How do I buy shares of ICON Public?

Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ICON Public's stock price today?

One share of ICLR stock can currently be purchased for approximately $256.05.

How much money does ICON Public make?

ICON Public has a market capitalization of $13.53 billion and generates $2.80 billion in revenue each year. The medical research company earns $332.33 million in net income (profit) each year or $3.93 on an earnings per share basis.

How many employees does ICON Public have?

ICON Public employs 15,730 workers across the globe.

Does ICON Public have any subsidiaries?

The following companies are subsidiares of ICON Public: Addplan Inc., Aptiv Solutions, Barton & Polansky Associates Inc., Beacon Bioscience Inc., BeijingWits Medical Consulting Ltd., C4 MedSolutions LLC, CHC Group LLC, CRN Holdings LLC, CRN North America LLC, Clinical Research Management, Clinical Resource Network LLC, Complete Healthcare Communications LLC, Complete Publication Solutions LLC, Cross Country Healthcare - Clinical Trial Services, DOCS Global Inc., DOCS Insourcing B.V., DOCS International B.V., DOCS International Belgium N.V., DOCS International Finland Oy, DOCS International France S.A.S., DOCS International Germany GmbH, DOCS International Nordic Countries A/S, DOCS International Poland Sp. z o.o., DOCS International Sweden AB, DOCS International Switzerland GmbH, DOCS International UK Limited, DOCS Italia S.R.L., DOCS Resourcing Limited, DOCS Ukraine LLC, Firecrest Clinical Ltd, Global Pharmaceutical Strategies Group LLC, ICON (LR) Limited, ICON Ankara Klinik Arastirma Dis Ticaret Anonim Sirketi, ICON CRO Malaysia SDN. BHD., ICON Chile Limitada, ICON Clinical International Unlimited Company, ICON Clinical Research (Beijing No.2) Co. Ltd, ICON Clinical Research (Beijing) Co. Ltd, ICON Clinical Research (Canada) Inc., ICON Clinical Research (New Zealand) Limited, ICON Clinical Research (Pte) Limited, ICON Clinical Research (Rus) LLC, ICON Clinical Research (Switzerland) GmbH, ICON Clinical Research (Thailand) Limited, ICON Clinical Research (U.K.) Limited, ICON Clinical Research Austria GmbH, ICON Clinical Research EOOD, ICON Clinical Research España S.L., ICON Clinical Research GmbH, ICON Clinical Research Hong Kong Limited, ICON Clinical Research India Private Limited, ICON Clinical Research Israel Limited, ICON Clinical Research Korea Yuhan Hoesa, ICON Clinical Research Korea Yuhan Hoesa (ICON Clinical Research Korea Ltd.), ICON Clinical Research LLC, ICON Clinical Research Limited, ICON Clinical Research México S.A. de C.V., ICON Clinical Research PTY Limited, ICON Clinical Research Perú S.A., ICON Clinical Research Property Development (Ireland) Limited, ICON Clinical Research S.A., ICON Clinical Research S.R.L., ICON Clinical Research SARL, ICON Clinical Research Services Philippines Inc., ICON Clinical Research Slovakia s.r.o., ICON Clinical Research Sp. z o.o., ICON Clinical Research Taiwan Limited, ICON Clinical Research d.o.o. Beograd, ICON Clinical Research s.r.o., ICON Contracting Solutions Holdings B.V., ICON Development Solutions Limited, ICON Early Phase Services LLC, ICON Global Treasury Limited, ICON Government and Public Health Solutions Inc., ICON Government and Public Health Solutions Inc. (formerly Clinical Research Management (ClinicalRM)), ICON Holdings Clinical Research International Limited, ICON Holdings Unlimited Company, ICON Investments Five Unlimited Company, ICON Investments Four Unlimited Company, ICON Investments Limited, ICON Japan K.K., ICON Klinikai Kutató Korlátolt Felelősségű Társaság, ICON Klinikai Kutató Korlátolt Felelősségű Társaság (ICON Clinical Research Limited Liability Company), ICON Laboratory Services Inc., ICON Pesquisas Clínicas LTDA., ICON US Holdings Inc., Improving Treatments Limited, Ispitivanja ICON d.o.o, Ispitivanja ICON d.o.o (ICON Research Ltd.), MMMM Consulting LLC, MMMM Group LLC, Managed Care Strategic Solutions L.L.C., Mapi Développement SAS, Mapi Group, Mapi Life Sciences Canada Inc., Mapi Life Sciences UK Limited, Mapi Research Trust, Mapi Research Trust*, Mapi SAS, Mapi USA Inc., MeDiNova Investigacion y Desarrollo S.L., MeDiNova Lakeside Clinical Research Limited, MeDiNova Limited, MeDiNova Merc (UK) Limited, MeDiNova Merc Clinical Research (SA) Pty Limited, MeDiNova Research, MedPass International, MediMedia Pharma Solutions, Molecular MD Corp., MolecularMD, Oxford Outcomes Limited, Oxford Outcomes Ltd, PMG Research, PMG Research Inc., PMG Research of Bristol LLC, PMG Research of Charleston LLC, PMG Research of Charlotte LLC, PMG Research of Christie Clinic LLC, PMG Research of Hickory LLC, PMG Research of Raleigh LLC, PMG Research of Rocky Mount LLC, PMG Research of Salisbury LLC, PMG Research of Wilmington LLC, PMG Research of Winston-Salem LLC, PRA Health Sciences, Pacific Research Associates Inc., Prevalere Life Sciences Inc., PriceSpective, Pricespective LLC, PubsHub LLC, Symphony Clinical Research Sp. z o.o., Timaq Medical Imaging, UCT (U.S.) Inc, VSK (Kenilworth) Limited, and Veeda Laboratories Ltd..

When was ICON Public founded?

ICON Public was founded in 1990.

What is ICON Public's official website?

The official website for ICON Public is www.iconplc.com.

Where are ICON Public's headquarters?

How can I contact ICON Public?

ICON Public's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at (531) 291-2000 or via fax at 353-1247-6260.

This page was last updated on 1/25/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.